PDF(Pubmed)
Abstract：
Background: This systematic review aimed to evaluate the impact of antiresorptive drug therapy on osseointegrated dental implants and the association with medication-related osteonecrosis of the jaw (MRONJ). Methods: A systematic search, including a computer search of several databases with specific keywords, a reference search, and a manual search of four key maxillofacial journals were performed. Relevant articles were then evaluated and those that fulfilled the five predetermined criteria were chosen to enter the final review. A total of 445 implants in 135 subjects were included in the eight studies analyzed in the final review. Results: The failure rate of dental implants after antiresorptive medication in the included studies was 23%, with 83% of failures attributed to MRONJ. The average time from antiresorptive drug initiation to MRONJ development was approximately 34 months, ranging from 3 months to 16 years. The majority of MRONJ cases were classified as stage 2, and all sites showed either complete healing or substantial mucosal coverage after treatment. Conclusions: This review highlights the significant impact of antiresorptive drugs on osseo- integrated implants, with MRONJ identified as a leading cause of implant failure. The potential role of peri-implantitis as a trigger for MRONJ is emphasized. Regular monitoring and maintaining good periodontal health, especially within the first three years of antiresorptive drug therapy initiation, are crucial for implant success. Physicians and dentists should provide comprehensive information to patients prescribed with antiresorptive drugs, emphasizing the need for an awareness of the risks of MRONJ in the context of osseointegrated implants. A longer term of follow-up is recommended to identify and manage MRONJ around dental implants in an early manner.
摘要：
背景：本系统综述旨在评估抗吸收药物治疗对骨整合牙种植体的影响以及与药物相关的颌骨坏死（MRONJ）的关系。方法：系统搜索，包括计算机搜索几个具有特定关键字的数据库，参考搜索，并对四个关键颌面轴颈进行了手动搜索。然后对相关文章进行评估，并选择符合五个预定标准的文章进入最终审查。在最终审查中分析的8项研究中，共包括135名受试者中的445个植入物。结果:纳入研究的抗再吸收药物治疗后种植牙的失败率为23%,83%的故障归因于MRONJ。从抗再吸收药物开始到MRONJ开发的平均时间约为34个月，从3个月到16年不等。大多数MRONJ病例被归类为2期，所有部位在治疗后显示完全愈合或粘膜覆盖。结论：这篇综述强调了抗吸收药物对骨整合植入物的显著影响，MRONJ被确定为植入物失败的主要原因。强调种植体周围炎作为MRONJ触发因素的潜在作用。定期监测并保持良好的牙周健康，特别是在开始抗吸收药物治疗的头三年内，对植入成功至关重要。医生和牙医应向服用抗吸收药物的患者提供全面的信息，强调需要在骨整合植入物的背景下认识MRONJ的风险。建议进行长期随访，以尽早识别和管理牙种植体周围的MRONJ。
